🔹 Adj. EPS: $1.39 (Est. $1.36) 😐; UP +7% YoY
🔹 Revenue: $8.29B (Est. $8.33B) 🔴; UP +2.5% YoY
🔹 Organic Revenue Growth: 4.1% YoY
🔹 Adj. Net Income: $1.79B (Est. $1.74B) 😐; UP +3% YoY
FY'25 Guidance
🔹 Adj. EPS: $5.44-$5.50 (Est. $5.45) 🟡
🔹 Organic Revenue Growth: 4.75%-5%
Q3'25 Segments
🔹 Cardiovascular Revenue: $3.04B (Est. $3.04B) 🟡; UP +3.7% YoY
- Cardiac Rhythm & Heart Failure: $1.55B (Est. $1.53B) 🟢; UP +5.1% YoY
- Structural Heart & Aortic: $874M (Est. $874.71M) 🟡; UP +3.7% YoY
- Coronary & Peripheral Vascular: $618M (Est. $632.14M) 🔴; UP +0.3% YoY
🔹 Neuroscience Revenue: $2.46B (Est. $2.45B) 🟢; UP +4.4% YoY
- Cranial & Spinal Technologies: $1.25B; UP +3.8% YoY
- Specialty Therapies: $732M; UP +0.8% YoY
- Neuromodulation: $476M; UP +12.0% YoY
🔹 Medical Surgical Revenue: $2.07B (Est. $2.13B) 🔴; DOWN -1.9% YoY
🔹 Diabetes Revenue: $694M (Est. $681.77M) 🟢; UP +8.4% YoY
Q3'25 Geographical Performance
🔹 U.S. Revenue: $4.24B; UP +2.8% YoY
🔹 International Revenue: $4.06B; UP +2.2% YoY
Announcements & Strategic Updates
🔸 U.S. FDA approval for additional PFA manufacturing site in Galway
🔸 CMS coverage for Renal Denervation expected by Oct 11, 2025
🔸 Exclusive distribution agreement with Contego Medical for carotid stenting
Management Commentary
🔸 CEO Geoff Martha: "We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth."
🔸 Interim CFO Gary Corona: "EPS came in above the high end of our guidance range. We were pleased with the operational performance of the business this quarter, turning mid-single digit organic growth into leveraged earnings."